SLC38A9, a member of the solute carrier family, is a protein that is intricately involved in amino acid transport and mTOR signaling. The activity of this protein can be influenced by several chemical activators through various signaling pathways. Compounds that elevate intracellular levels of cyclic adenosine monophosphate (cAMP) can enhance the functional activity of SLC38A9. This elevation can be achieved through direct stimulation of adenylyl cyclase or by inhibiting the degradation of cAMP via phosphodiesterase inhibition. Increased cAMP levels result in a cascade of events that may lead to the activation of protein kinase A (PKA) and subsequent phosphorylation of downstream targets, which could include pathways that indirectly influence SLC38A9 activity. Additionally, certain phosphodiesterase inhibitors specifically elevate cyclic guanosine monophosphate (cGMP) levels, which can also modulate pathways that intersect with cAMP signaling, indirectly supporting the activation of SLC38A9.
Beyond the cAMP/cGMP axis, other molecular entities function through distinct mechanisms to activate SLC38A9. Compounds that inhibit tyrosine kinases or phosphoinositide 3-kinases (PI3K) can alter downstream signaling pathways, potentially leading to the activation of SLC38A9. For example, by modulating the AKT pathway, a PI3K inhibitor may indirectly activate SLC38A9 as part of the cellular response to changes in nutrient availability or growth signals. Similarly, inhibitors of protein kinase C may alter cellular signaling in a manner that promotes SLC38A9 activity. Furthermore, certain polyphenols activate sirtuin pathways, which are known to influence the mammalian target of rapamycin (mTOR) signaling, a key regulator of amino acid sensing and transport.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Directly stimulates adenylyl cyclase, increasing intracellular cAMP levels, thereby potentially enhancing SLC38A9 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-selective phosphodiesterase inhibitor, prevents cAMP degradation, potentially supporting SLC38A9 function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Selective inhibitor of phosphodiesterase 4, increasing cAMP concentrations, which may enhance SLC38A9 activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
β-adrenergic agonist that increases cAMP levels, possibly facilitating SLC38A9 activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Inhibits phosphodiesterase 5, increasing cGMP levels, which can indirectly affect cAMP pathways, aiding SLC38A9 activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Inhibits phosphodiesterase 1, elevating cAMP and cGMP levels, potentially contributing to SLC38A9 activation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Phosphodiesterase 3 inhibitor, increasing cAMP levels, which could enhance SLC38A9 functional activity. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $26.00 $50.00 $99.00 $150.00 $1887.00 | 40 | |
Known to inhibit protein kinase C, which may lead to alterations in signaling pathways that activate SLC38A9. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Tyrosine kinase inhibitor, can alter downstream signaling, potentially promoting SLC38A9 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, modulates downstream AKT pathway, which may result in the functional activation of SLC38A9. | ||||||